Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Share Market News
Top brokers name 3 ASX shares to buy right now
⏸️ ASX Shares
Where to invest $20,000 into ASX shares for market-beating returns
Growth Shares
Cochlear and these ASX 200 shares could be fantastic buy and hold investments
⏸️ ASX Shares
ASX 200 closes 0.4% higher, Cochlear share price up 6%
Share Market News
ASX 200 up 0.55%: Cochlear jumps on FDA approval, Adbri crushed on contract loss
Share Gainers
Cochlear share price charges higher on US FDA update
⏸️ ASX Shares
Why I would buy and hold a2 Milk and this ASX 200 share until 2030
Share Market News
These are 2 quality ASX shares to buy with $2,000
⏸️ Investing
Why National Storage shares are a great "set and forget" option for your portfolio
⏸️ ASX Shares
Give your portfolio a boost with these ASX blue chip shares
Share Market News
Australian businesses are running out of cash
⏸️ ASX Shares
These fantastic healthcare ASX shares could make you wealthy
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
